Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors (PASSILCORT)
Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC
Sponsor: Columbia University
Terminated
Lack of funding
This PHASE2 trial investigates ACTH-producing Pituitary Tumour and Pituitary Tumor and is currently terminated or withdrawn. Columbia University leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
May 2021 — Dec 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — May 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Columbia University
For direct contact, visit the study record on ClinicalTrials.gov .